ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway

BACKGROUND: ER-α36, a novel ER-α66 variant, has been demonstrated to promote tamoxifen resistance in breast cancer cells. However, the role and mechanisms of ER-α36 in cisplatin resistance of breast cancer cells remain unclear. This study investigates the expression and role of ER-α36 in cisplatin r...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Linlin, Zou, Jiao, Zhao, Yuanyin, Jiang, Xiaomei, Wang, Yang, Wang, Xiangwei, Chen, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6019204/
https://www.ncbi.nlm.nih.gov/pubmed/29940998
http://dx.doi.org/10.1186/s13046-018-0798-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6019204/
https://www.ncbi.nlm.nih.gov/pubmed/29940998
http://dx.doi.org/10.1186/s13046-018-0798-z

Ejemplares similares